Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opexa offering cuts stock in half to fund MS immunotherapy

This article was originally published in Scrip

Executive Summary

Opexa Therapeutics priced 12 million shares after the market closed on 7 August at $1.50 per share – nearly half of the company's $2.92 closing price – to raise $18 million for its ongoing Phase IIb clinical trial for the personalized multiple sclerosis immunotherapy Tcelna.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC022395

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel